Coagulation Factor Ix Human

CHEMBL4297986 Phase 4 Aprovado Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A naturally derived clotting protein used to treat hemophilia B, a condition where the blood cannot clot properly due to a deficiency in factor IX. It helps control and prevent bleeding episodes in affected patients.

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A naturally derived clotting protein used to treat hemophilia B, a condition where the blood cannot clot properly due to a deficiency in factor IX. It helps control and prevent bleeding episodes in affected patients.

Yes, Coagulation Factor Ix Human is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297986. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.